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Abstract
New studies show a possible benefit of combining Gemcitabine, 
Oxaliplatin and Cetuximab for the treatment of intrahepatic tu-
mors. However, there is currently no consensus in the literature. 
Hence, this article contributes to the debate by presenting a case of 
cholangiocarcinoma (biliary tract cancer), treated with a modified 
Gemcitabine, Oxaliplatin and Cetuximab protocol, which evolved to 
a considerable regression of the tumor and a complete radiologic 
response assessed by PET-CT Scan. The case report is of a female 
adult, who presented with a cholangiocarcinoma extending to he-
patic segments V and VIII which met unresectable criteria. She was 
submitted to chemotherapy, consisting of a combination of Gemci-
tabine, Oxaliplatin and Cetuximab for a prolonged period, followed 
by a maintenance interval of Cetuximab monotherapy. After the 
8th cycle, the patient presented better hepatic biomarker levels; 
after 15 months of treatment, our team achieved optimal partial 
radiologic response assesed by PET-CT scan as shown; after 15 
months of treatment, a MRI scan showed a reduced and resectable 
tumor. Our case report suggests use of the Gemcitabine + Oxali-
platin (GEMOX) plus Cetuximab protocol as a neoadjuvant setting 
for patients with unresectable cholangiocarcinoma. Additionally, 
our case report confirms the GEMOX plus Cetuximab protocol can 
be modified according to clinical response so patients can obtain 
maximum therapeutic gain despite minor or adverse reactions.
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Introduction
Intra-hepatic cholangiocarcinoma is a rare tumor of epithelial cells of 
the biliary tract, with an incidence of 1-2 cases per 100,000 in habitants 
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in the United States. This tumor has poor prognosis 
with five years survival rates of only 5-10%. The cu-
rrent treatment of choice is surgery, but in cases of 
structural impairment of the liver and unresectable 
tumors, chemotherapy is indicated before surgical 
treatment [1-5].
The use of Oxaliplatin combined with Gemcita-
bine (GEMOX) has proven to be highly effective for 
the treatment of intrahepatic cancer, particularly 
cholangiocarcinoma. Despite the small increase in 
the survival rate (four months) of patients who used 
this combination compared to Gemcitabine alone, 
it is still relevant to look for new therapeutic al-
ternatives. New studies show a possible benefit in 
implementing targeted therapy with the use Epi-
dermal Growth Factor Receptor (EGFR) inhibitors, 
such as Cetuximab, to the GEMOX protocol. This 
finding has been confirmed by one phase II study 
[6], which found satisfactory therapeutic responses, 
while, another study, controversially, found no such 
benefit [7].
This article is therefore relevant to the debate as 
it presents the case of a patient with cholangiocar-
cinoma, who was treated at our institution with a 
modified GEMOX and Cetuximab protocol, which 
resulted in a positive outcome. 
Case Presentation
Written informed consent was obtained from the 
patient for publication of this case report and any 
accompanying images.
After recommended by her hepatologist, a 56 
year-old female patient looked for the oncology 
clinic with a biopsy result of an intrahepatic tumor. 
She also had laboratory test results that showed 
high baseline levels of Gamma Glutamyl Transfe-
rase (Gamma GT) (115 U/L) and alpha-fetalprotein 
(AFP). Serum levels of aspartate aminotransfera-
se (AST), alanine aminotransaminase (ALT), and 
lactic dehydrogenase are shown in figure 2. The 
Eastern Cooperative Oncology Group (ECOG) per-
formance status was zero.
Following Magnetic Resonance Imaging (MRI) 
scans and immunohistochemistry studies for clini-
cal staging and definition of treatment, the patient 
was diagnosed with intrahepatic cholangiocarcino-
ma in segments V and VIII. The tumor had a lobu-
lated surface, a baseline diameter of approximately 
5 cm (Figure 1) and a positive cytokeratin-7. The 
MRI also showed an increase in the tumor area 
with some perilesional perfusion abnormalities, 
unclear margins and a dilatation of the intrahepa-
tic bile ducts. Due to the large size within the liver 
tree, this tumor was considered unresectable and 
chemotherapy protocol was performed.
Initially, we opted for the GEMOX (Gemcitabine 
1000 mg/m2 and Oxaliplatin to 100 mg/m2) plus 
Cetuximab (250/mg/m2 weekly) protocol, which 
recommends their administration every two weeks 
for 8 cycles. At her follow-up consult, the patient 
complained of some expected adverse effects of 
the chemotherapy like mild asthenia and Grade 
I rashes, without the need of changing the che-
motherapy protocol. After the fifth cycle, the pa-
tient had the same mild clinical presentation of 
adverse effects, as well as a better clinical presen-
tation of her disease. The latter assessment was 
based on her hepatic function biomarkers, such as 
Gamma GT (125 U/L), which justified recommen-
Figure 1:  Magnetic Resonance Imaging in which 
liver injury is evident in the segments V 
and VIII measuring approximately 5 cm.
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ding her to finish the 12 cycles of the treatment 
protocol. 
She was treated with GEMOX plus Cetuximab 
until the end of eight cycles and her care was then 
extended with four more cycles, according to a 
standard protocol. After completing the 8 cycles 
of standard approach and 4 administration cycles, 
we proceeded with Cetuximab (250/mg/m2 wee-
kly) maintenance chemotherapy every two weeks. 
The patient reported only peripheral neuropathy 
induced by Oxaliplatin, grade II by National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE).
After the eighth cycle of treatment, the patient 
showed reduced hepatic function biomarker le-
vels, with a lower Gamma GT (95 U/L), which con-
tinued to fall until the last evaluated cycle (62 U/L). 
This clinically demonstrates not only the stabiliza-
tion of the disease, but also its regression either 
in clinical or laboratorial response. The evolution 
of patient’s biomarkers during treatment can be 
seen in figure 2.
Twelve months after the start of her treatment, 
positron emission tomography-computed tomo-
graphy (PET-CT) imaging showed an optimal 
partial response and optimal clinical response to 
Figure2: Evolution of patient’s biomarkers during treatment.
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the therapy. After fifteen months of treatment, 
a MRI also showed a remarkable reduction in 
tumor size with dimensions of 2.4x1.8 cm at its 
greatest axis.
Currently, the patient is under surgical evaluation 
by the hepatology department. She maintains satis-
factory radiological responses with a tumor reduced 
to 2.4x1.8 cm in size (Figure 3), and a PET-CT scan 
showing a complete radiological response. 
Discussion
The diagnosis of intrahepatic cholangiocarcinoma is 
challenging due to the late presentation of symp-
toms and tumors are often at an unresectable sta-
ge at the time of diagnosis. The choice for initial 
therapeutic approach includes surgery or neo adju-
vant chemotherapy [2, 6-8]. The standard primary 
protocol, GEMOX (Gemcitabine 1000 mg/m2 and 
Oxaliplatin 100 mg/m2), was signed after the ABC-2 
Trial, a randomized clinical study that demonstrated 
an improvement in the overall survival of these pa-
tients, with statistically significant results compared 
to single treatment with Gemcitabine considering 
adjuvant setting [1].
Even with the improvement in median overall 
survival of patients treated with GEMOX, pa-
tients with advanced biliary tract cancer still have 
a poor clinical outcome, with an average of less 
than one year overall survival with treatment. New 
treatments are continually proposed to increase 
the overall survival and disease-free survival of 
these patients [6-8].
Studies with target-specific therapy are being tes-
ted and several possible receptors may be related to 
these types of tumors. Tyrosine kinase receptors for 
EGFR and for the Mitosis Activator Protein MAPK/
ERK kinase (MEK) are found in cholangiocarcinomas 
and may be relevant for finding alternative thera-
peutics [1, 6].
A phase II study by Gruenberger et al demons-
trated the use of Gemcitabine, Oxaliplatin plus Ce-
tuximab for 12 cycles, in patients with advanced or 
metastatic intrahepatic cancer. Thirty patients were 
analyzed with a mean age of 68 years and all were 
submitted to the same protocol. The study presen-
ted satisfactory response rates of 63% in the trea-
ted group and three (10%) of these had complete 
disease eradication [1].
In contrast, a randomized phase II clinical study, 
BINGO, evaluated 150 patients treated with Gem-
citabine and Oxaliplatin. Seventy-six patients were 
treated with GEMOX plus Cetuximab and the re-
mainder with GEMOX alone. All were given the pri-
mary treatment recommended for unresectable or 
metastatic cholangiocarcinoma. The results showed 
a median overall survival increase of 1.4 months for 
those patients treated with the standard GEMOX 
protocol alone [6].
In our case report, our patient was submitted 
to the GEMOX plus Cetuximab protocol for 12 
months, followed by maintenance with Cetuximab, 
to which she responded with a considerable clinical 
regression of the disease for more than 20 months. 
Subsequently, a PET-CT scan showed complete ra-
diologic response and a MRI showing significant 
regression of the tumor. In summary, the tumor 
Figure 3:  Magnetic Resonance Imaging in which 
liver injury is evident in the segments 
V and VIII measuring approxima-
tely 2.4x1.8 cm, after 16 months of 
treatment.




Vol. 8 No. 86
doi: 10.3823/1685
© Under License of Creative Commons Attribution 3.0 License 5
that had been unresectable at the beginning of 
treatment successfully reduced to a size suitable for 
full surgical resection.
These results show that, despite the recent con-
troversial indications, as suggested by the BINGO 
study, the GEMOX plus Cetuximab protocol may 
be effective for some patients, as demonstrated in 
the study of Gruenberger et and in this case re-
port. Therefore, we suggest that the GEMOX plus 
Cetuximab protocol could be used as primary or 
alternative for patients with a progressing disease 
submitted to the GEMOX protocol. Additionally, 
our case report affirms that the GEMOX plus Ce-
tuximab protocol can be modified according to cli-
nical response so patients can obtain a maximum 
therapeutic gain [6].
Conclusion
Further studies are needed and alternative proto-
cols should be studied in randomized clinical trials 
to better outline the use of epidermal growth bloc-
kers and to develop improved therapeutic strate-
gies in an attempt to increase the survival time of 
the patient carriers of such tumors with unfavora-
ble prognosis.
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